CMS Finalizes TAVR Coverage Update; Stifel Sees Boost for Edwards Lifesciences
CMS issued a finalized national coverage determination for transcatheter aortic valve replacement (TAVR) that largely mirrors its June proposal. Stifel analysts view the decision as constructive for the TAVR market and for Edwards Lifesciences, given the company's leadership position. The final ruling preserves volume and site standards, affirms su…